Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$8.41 USD
+0.22 (2.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.41 USD
+0.22 (2.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $8.40 -0.01 (-0.12%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth C Momentum D VGM
Zacks News
Factors Setting the Tone for Bristol-Myers (BMY) Q1 Earnings
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports first-quarter 2020 results.
Cronos (CRON) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with its pipeline progress, when Cronos (CRON) reports Q1 results.
Will Soliris & Ultomiris Drive Alexion's (ALXN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Soliris and Ultomiris along with other pipeline updates, when Alexion (ALXN) reports first-quarter 2020 results.
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports first-quarter 2020 results.
Will Eylea & Dupixent Drive Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates, when Regeneron (REGN) reports first-quarter 2020 results.
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, DexCom, ViewRay, Chemed and Sage Therapeutics
Buy 5 Top Health Care Stocks Ahead of Q1 Earnings Results
by Nalak Das
Economic activities came almost to a standstill in March. However, one sector that witnessed heightening activities is health care.
Sage Therapeutics' Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Sage Therapeutics.
How Sage Therapeutics (SAGE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Sage Therapeutics (SAGE) in Focus: Stock Moves 9.3% Higher
by Zacks Equity Research
Sage Therapeutics (SAGE) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Why Sage Therapeutics (SAGE) Stock Might be a Great Pick
by Zacks Equity Research
Sage Therapeutics (SAGE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Proteostasis (PTI) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Proteostasis Therapeutics (PTI) to provide updates on its pipeline when its releases fourth-quarter 2019 results.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to have increased in the fourth quarter driven by clinical studies on its lead pipeline candidate, Zygel.
Why Earnings Season Could Be Great for Sage Therapeutics (SAGE)
by Zacks Equity Research
Sage Therapeutics (SAGE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NuCana (NCNA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect NuCana (NCNA) to provide updates on its pipeline when it releases fourth-quarter results.
Actinium (ATNM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Actinium (ATNM) reports fourth-quarter 2019 results.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2019 results.
Assertio (ASRT) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 earnings call, Assertio (ASRT) is likely to provide an update on its recently implemented cost-saving initiatives and the sales performance of its marketed drugs.
AcelRx (ACRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
During Q4 investors' call, AcelRx (ACRX) is likely to provide an update on the sales uptake of its recently-unveiled product Dsuvia, which is approved for acute pain management.
Coherus (CHRS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Coherus BioSciences (CHRS) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Intellia (NTLA) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Intellia (NTLA) is likely to provide an update on the IND application for its lead candidate NTLA-2001, currently being developed to address transthyretin amyloidosis.
Guardant Health (GH) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Guardant Health's (GH) Q4 earnings call, investors' focus will be on the updates related to Guardant360 test and the colorectal cancer screening rates of its LUNAR-2 blood test.
Cyclacel (CYCC) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Cyclacel (CYCC) to provide updates on its pipeline when it releases fourth-quarter 2019 results.
Epizyme (EPZM) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
We expect Epizyme (EPZM) to provide commercialization updates on its sarcoma drug when it releases fourth-quarter 2019 earnings.
What's in Store for Aimmune (AIMT) This Earnings Season?
by Zacks Equity Research
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.